Obesity

The Go for Bold initiative, which aims to help individuals in Washington County, Maryland, lose 1 million lb by 2030, serves as a successful, replicable model for community-wide health improvement.

In a cohort of US veterans, there were reduced risks of adverse clinical outcomes in people with SUDs and of developing an SUD in those taking GLP-1s.

FDA approves 4-dose KwikPen for tirzepatide (Zepbound; Eli Lilly), offering a full month of weight management treatment in 1 device.

New GLP-1 pills challenge injections as competition, and discussions of possible Medicare coverage could push prices down.

Oral Wegovy reshapes GLP-1 costs: cash pay can be cheaper, insurance pricing often matches shots, and coverage hinges on employer benefits and coding.

City leaders share real-world GLP-1 coverage tactics, showing how public employers balance access, costs, and lasting weight-management outcomes with data-driven oversight.

Oral GLP-1 costs, insurance gaps, and formulary switches reshape drug pricing and access—learn how to navigate coverage.

Individuals can use these 5 ways to minimize their cancer risk during National Cancer Prevention Month and beyond.

To protect patients, the FDA will restrict ingredients in unapproved compounded GLP‑1 drugs and crack down on misleading marketing.

Oral semaglutide (Wegovy; Novo Nordisk) expands GLP-1 weight-loss options, but pharmacy budgets and health care cost pressures persist.

Oral Wegovy shifts GLP-1 obesity costs: insurance may match injectables, while cash-pay and pharmacy platforms unlock lower prices and aid programs.

Obesity market overview for employers: data on GLP-1s for obesity, digital solutions, and benefit strategies to control costs and outcomes.

Adults who are underweight, overweight, or obese face higher medical expenditures, varying by age, sex, and care setting.

Explore the evolving GLP-1 landscape with insights from industry experts, shaping future health strategies and plan designs for employers.

Aleata Postell discusses CenterWell Pharmacy's partnership with Eli Lilly to dispense FDA-approved obesity management drugs.

Nimbus Therapeutics and Eli Lilly announce their partnership to develop a novel oral drug for patients with obesity and other metabolic disorders.

Our top 5 obesity articles of 2025 highlight GLP-1 prescribing trends, insurance coverage, co-pay caps, real-world use, and access challenges.

The FDA approves Wegovy, the first oral GLP-1 pill, offering a new weight loss solution for those struggling with obesity and overweight.

The top Managed Care Cast episodes explored wellness visits, weight loss drug access, neurospine care, public health policy, and ketamine-assisted therapy.

Glucagon-like peptide 1 (GLP-1) receptor agonists offer promise in weight and cardiovascular risk reduction, but their use must complement—not replace—lifestyle interventions within a holistic, patient-centered care model.

A phase 2 trial demonstrated substantial weight loss with the long-acting peptide–antibody conjugate, as well as other cardiometabolic improvements.

Explore the evolving landscape of biologics in metabolic syndrome treatment, highlighting GLP-1 analogs and PCSK9 inhibitors for improved patient outcomes.

The guidelines highlight the need for lifelong obesity management, early diagnosis, comorbidity prevention, and patient-centered care.

Discontinuing GLP-1 use before or early in pregnancy raises gestational weight gain, birth weight percentile, and the risk of pregnancy complications.

Research shows a sharp rise in bisphenol-attributable metabolic disease since 2000, with annual costs exceeding $250 billion in North America.